• Publications
  • Influence
Characterization of rubber particles and rubber chain elongation in Taraxacum koksaghyz
BackgroundNatural rubber is a biopolymer with exceptional qualities that cannot be completely replaced using synthetic alternatives. Although several key enzymes in the rubber biosynthetic pathwayExpand
  • 77
  • 7
Identification and characterization of a family of secretion‐related small GTPase‐encoding genes from the filamentous fungus Aspergillus niger : a putative SEC4 homologue is not essential for growth
DNA fragments containing genetic information for five secretion‐related small GTPases of Aspergillus niger (srgA–E) were isolated and identified as members of different Rab/Ypt subfamilies. ThisExpand
  • 61
  • 6
Serum-Mediated Inhibition of Enzyme Replacement Therapy in Fabry Disease.
Fabry disease (FD) is a progressive multisystemic disorder, treatable with recombinant enzyme replacement therapy (agalsidase). However, recent studies suggest an endogenous inhibition of agalsidaseExpand
  • 64
  • 4
  • PDF
Molecular Cloning and Characterization of Rubber Biosynthetic Genes from Taraxacum koksaghyz
Rubber biosynthesis requires the action of specific enzymes known as cis-prenyltransferases (CPTs). These enzymes are responsible for the sequential addition of isopentenyl pyrophosphate units to theExpand
  • 59
  • 4
Down-Regulation of Small Rubber Particle Protein Expression Affects Integrity of Rubber Particles and Rubber Content in Taraxacum brevicorniculatum
The biosynthesis of rubber is thought to take place on the surface of rubber particles in laticifers, highly specialized cells that are present in more than 40 plant families. The small rubberExpand
  • 55
  • 2
  • PDF
Soluble Adenylyl Cyclase in Vascular Endothelium: Gene Expression Control of Epithelial Sodium Channel-&agr;, Na+/K+-ATPase-&agr;/&bgr;, and Mineralocorticoid Receptor
The Ca2+- and bicarbonate-activated soluble adenylyl cyclase (sAC) has been identified recently as an important mediator of aldosterone signaling in the kidney. Nuclear sAC has been reported toExpand
  • 16
  • 2
Fabry disease under enzyme replacement therapy—new insights in efficacy of different dosages
Background Fabry patients on reduced dose of agalsidase-beta or after switch to agalsidase-alfa show a decline in estimated glomerular filtration rate (eGFR) and an increase of the Mainz SeverityExpand
  • 11
  • 2
Patients with Fabry disease after enzyme replacement therapy dose reduction versus treatment switch.
Because of the shortage of agalsidase-beta in 2009, many patients with Fabry disease were treated with lower doses or were switched to agalsidase-alfa. This observational study assessed end-organExpand
  • 49
  • 1
  • PDF
Patients with Fabry Disease after Enzyme Replacement Therapy Dose Reduction and Switch-2-Year Follow-Up.
Because of the shortage of agalsidase-β supply between 2009 and 2012, patients with Fabry disease either were treated with reduced doses or were switched to agalsidase-α. In this observational study,Expand
  • 29
  • 1
  • PDF
Alpha-Galactosidase A p.A143T, a non-Fabry disease-causing variant
BackgroundFabry disease (FD) is an X-linked multisystemic disorder with a heterogeneous phenotype. Especially atypical or late-onset type 2 phenotypes present a therapeutical dilemma.MethodsToExpand
  • 24
  • 1